Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of TD-1473 in ulcerative colitis
MOH_2019-06-05_006076Phase 3Recruiting
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of izencitinib in autoimmune colitis (3 arms), sponsored by Theravance Biopharma, Inc. Started Apr 2019; status: recruiting.
02
Drugs
izencitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2019-06-05_006076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-05_006076.